Back to Search
Start Over
Real-world treatment patterns of renal anemia in hemodialysis patients
- Source :
- Medicine. 99:e18749
- Publication Year :
- 2020
- Publisher :
- Ovid Technologies (Wolters Kluwer Health), 2020.
-
Abstract
- A multicenter cohort study.The DialysisNet was previously developed for the management of hemodialysis (HD) patients based on the American Society for Testing and Materials Continuity of Care Records by metadata transformation. DialysisNet is a dialysis patient management program created by using the personal health record care platform to overcome the problems of registry studies, in real-time.Here, we aimed to investigate the pattern of treatment for renal anemia in HD patients using DialysisNet.We performed a multicenter cohort study among HD patients who were treated at one of the three Korean university-affiliated hospitals from January 2016 to December 2016. Subjects were divided into 4 hemoglobin variability groups by quartiles. The variable anemia treatment pattern was reviewed. To determine renal anemia treatment patterns, we automatically collected information on the practice of anemia treatment patterns such as erythropoietin stimulating agent (ESA) doses and administration frequencies, and targeted hemoglobin maintenance rate. Individual hemoglobin variabilities were expressed as (standard deviations)/(√(n/[n-1]).The records of 159 patients were analyzed (Hospital A: 35, Hospital B: 21, Hospital C: 103). Mean patients' age was 65.6 ± 12.8 years, and 61.6% were men. Overall, hemoglobin level was 10.5[7.43;13.93] g/dL. 158 (99.3%) patients were using ESA; and overall, the epoetin alfa dose was 33,000[4000;136,800] U per week. Hemoglobin levels (P = .206) and epoetin alfa doses were similar (P = .924) for patients with different hemoglobin variabilities. The hemoglobin target maintenance rate was lower in the highest hemoglobin variability group than in the lowest variability group (P = .045).In this study, detailed information on the actual anemia treatment patterns were obtained using the DialysisNet. We expect that DialysisNet will simplify and improve the renal anemia management for both dialysis patients and health care providers.
- Subjects :
- medicine.medical_specialty
Anemia
business.industry
medicine.medical_treatment
Epoetin alfa
General Medicine
medicine.disease
03 medical and health sciences
0302 clinical medicine
Quartile
030220 oncology & carcinogenesis
Internal medicine
Cohort
medicine
030212 general & internal medicine
Hemoglobin
Hemodialysis
business
Dialysis
Cohort study
medicine.drug
Subjects
Details
- ISSN :
- 15365964 and 00257974
- Volume :
- 99
- Database :
- OpenAIRE
- Journal :
- Medicine
- Accession number :
- edsair.doi...........f5c1bddd950417d9276e37b1b62c1fff
- Full Text :
- https://doi.org/10.1097/md.0000000000018749